Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.10 | N/A | -1.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.10 | N/A | -1.85% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their pipeline and emphasized the importance of upcoming clinical trials. They acknowledged the current financial results but are optimistic about future opportunities.
Management highlighted ongoing efforts in product development.
They expressed confidence in long-term growth despite current challenges.
Krystal Biotech's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 0.38%. This could indicate that investors are optimistic about the company's future potential despite the current financial results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROOKFIELD RENEW PAR
Aug 5, 2022